SAGE-324

DRUG3 trials

Sponsors

Sage Therapeutics

Conditions

Essential Tremor

Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

CompletedNCT04305275

Sage TherapeuticsEssential Tremor

Start: 2020-05-19End: 2021-02-15Updated: 2024-04-17

Study to Evaluate SAGE-324 in Participants With Essential Tremor

CompletedNCT05173012

Sage TherapeuticsEssential Tremor

Start: 2022-01-05End: 2024-05-16Updated: 2025-05-16

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

TerminatedNCT05366751

Sage TherapeuticsEssential Tremor

Start: 2022-06-03End: 2024-09-10Updated: 2025-08-01

Related Papers

A Randomized Phase 2 <scp>KINETIC</scp> Trial Evaluating <scp>SAGE</scp>‐324/<scp>BIIB124</scp> in Individuals with Essential Tremor

Movement Disorders2024-02-153 citations